Related Experiment Video
Updated: Apr 21, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Simvastatin attenuates angiotensin II‑induced inflammation and oxidative stress in human mesangial cells
Fengxiang Zhang1, Dapeng Sun2, Junjiang Chen2
1Department of Anatomy, China Medical University, Shenyang, Liaoning 110001, P.R. China.
Insights
Simvastatin effectively reduces inflammation and oxidative stress in human mesangial cells stimulated by angiotensin II. This study reveals simvastatin
Area of Science:
- Nephrology and Pharmacology
- Molecular Biology and Cellular Signaling
Background:
- Chronic kidney disease (CKD) is characterized by inflammation and oxidative stress.
- Angiotensin II (Ang II) exacerbates inflammation and oxidative stress in kidney cells.
- Understanding therapeutic interventions for CKD is crucial.
Purpose of the Study:
- To investigate the effects of simvastatin on Ang II-induced inflammation and oxidative stress in human mesangial cells (HMCs).
- To elucidate the underlying molecular mechanisms of simvastatin's action in HMCs.
Main Methods:
- Human mesangial cells (HMCs) were treated with varying concentrations of simvastatin followed by Ang II stimulation.
- Quantitative polymerase chain reaction (qPCR) and western blotting were used to analyze gene and protein expression.
- Dihydroethidium staining and enzyme-linked immunosorbent assay (ELISA) measured reactive oxygen species and prostaglandin E2 levels.
Main Results:
- Simvastatin dose-dependently suppressed Ang II-induced mRNA expression of inflammatory markers (MCP-1, TNF-α, IL-1β, IL-6).
- Simvastatin reduced reactive oxygen species, prostaglandin E2, and protein expression of COX-2, NADPH oxidase, and phosphorylated NF-κB p65.
- Simvastatin significantly increased peroxisome proliferator-activated receptor γ (PPARγ) protein expression.
Conclusions:
- Simvastatin mitigates inflammation and oxidative stress in Ang II-stimulated HMCs.
- The protective effects involve modulation of COX-2, PPARγ, NF-κB, NADPH oxidase, and PKC signaling pathways.
- Simvastatin demonstrates potential as a therapeutic agent for CKD by targeting key inflammatory and oxidative stress pathways.
Abstract:
Chronic kidney disease (CKD) is an intractable disease in which inflammation and oxidative stress are important. In the present study, the effect of simvastatin on inflammation and oxidative stress induced by angiotensin II (Ang II) in human mesangial cells (HMCs) and its corresponding mechanism was examined. In the in vitro experiment, HMCs were pretreated either without additives (control group) or with simvastatin at different concentrations (0, 0.1, 1 or 10 µM) for 1 h and were then stimulated by Ang II (1 µM) for 24 h. Following stimulation, the cells were collected for analysis using quantitative polymerase chain reaction, western blotting and dihydroethidium staining. The supernatant of the cells was collected and analyzed using an enzyme‑linked immunosorbent assay. The results demonstrated that simvastatin suppressed the increased mRNA expression of monocyte chemoattractant protein‑1, tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6 and the content of reactive oxygen species induced by Ang II in a dose‑dependent manner. In addition, simvastatin decreased the protein expression of cyclooxygenase‑2 (COX‑2), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and protein kinase C (PKC) as well as the content of prostaglandin E2 and the phosphorylation level of nuclear factor‑κB (NF‑κB) p65 in a dose‑dependent manner. Furthermore, simvastatin significantly increased the protein expression of peroxisome proliferator‑activated receptor γ (PPARγ). Therefore, simvastatin suppressed inflammation and oxidative stress in Ang II‑stimulated HMCs via COX‑2, PPARγ, NF‑κB, NADPH oxidase and PKCs, thereby exerting a protective effect on CKD.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
